CLOs on the Move

CoorsTek Medical

www.coorstekmedical.com

 
At CoorsTek Medical, our vision is to make lives measurably better. We are the partner of choice for medical innovators and medical-device providers worldwide whose success requires access to leading-edge medical device development experts and the related set of specialized product development and manufacturing capabilities.
  • Number of Employees: 250-1000
  • Annual Revenue: $0-1 Million
  • www.coorstekmedical.com
  • 13600 HERITAGE PARKWAY FORT WORTH
    TEXAS, TX USA 76177
  • Phone: 877.583.067
  • Fax: 817-890-4099

Executives

Name Title Contact Details

Similar Companies

Lyntek Medical Technologies

Lyntek Medical Technologies is a Draper, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Parter Medical Products

Parter Medical Products, Inc. is a Carson, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Probed Medical Technologies

Probed Medical Technologies is a Abbotsford, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Mededge Inc

Mededge Inc is a Los Angeles, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

T2 Biosystems

At T2 Biosystems, we are united in our mission: to improve patient outcomes, lower mortality rates and reduce the cost of healthcare by helping medical professionals make targeted treatment decisions earlier. By leveraging the power of our innovative and proprietary T2 Magnetic Resonance (T2MR) platform, T2 Biosystems’ diagnostics are designed to provide faster, easier and more accurate results than traditional methodologies. T2 Biosystems is currently targeting a range of critically underserved healthcare conditions, focusing initially on those for which a rapid diagnosis will serve an important dual role – saving lives and reducing costs. Our T2Candida Panel tackles sepsis and is the first FDA-cleared diagnostic panel requiring no blood culture – delivering more accurate results in hours versus days. Other ongoing development efforts include bacterial and hemostasis panels, as well as a Lyme disease partnership with Canon Life Sciences. Over 100 studies published in peer-reviewed journals have featured T2MR technology in a breadth of applications, including the direct detection and measurement of targets in various sample types, such as whole blood, plasma, serum, saliva, sputum and urine. With limits of detection as low as 1 CFU/mL, we believe T2MR technology will drive the next generation of diagnostics.